| 351 |
24368888 | Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes. | 2013 |
1 |
| 352 |
24501689 | Biochemical and functional analyses of gp130 mutants unveil JAK1 as a novel therapeutic target in human inflammatory hepatocellular adenoma. | 2013 Dec 1 |
2 |
| 353 |
22279053 | JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths. | 2012 Mar 22 |
1 |
| 354 |
22281165 | Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis. | 2012 Oct |
1 |
| 355 |
22319590 | STAT3 is activated by JAK2 independent of key oncogenic driver mutations in non-small cell lung carcinoma. | 2012 |
1 |
| 356 |
22375970 | JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. | 2012 Mar 1 |
1 |
| 357 |
22375971 | A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. | 2012 Mar 1 |
1 |
| 358 |
22399854 | Ruxolitinib for the treatment of myelofibrosis: its clinical potential. | 2012 |
2 |
| 359 |
22474318 | Ruxolitinib: the first FDA approved therapy for the treatment of myelofibrosis. | 2012 Jun 1 |
1 |
| 360 |
22544377 | U.S. Food and Drug Administration approval: ruxolitinib for the treatment of patients with intermediate and high-risk myelofibrosis. | 2012 Jun 15 |
1 |
| 361 |
22700718 | Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors. | 2012 Aug 16 |
2 |
| 362 |
22718840 | Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. | 2012 Aug 9 |
2 |
| 363 |
22830345 | Biology and clinical management of myeloproliferative neoplasms and development of the JAK inhibitor ruxolitinib. | 2012 |
1 |
| 364 |
22852872 | Splenomegaly in myelofibrosis--new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors. | 2012 Aug 1 |
1 |
| 365 |
23042420 | Advances in the management of myelofibrosis. | 2012 Oct |
1 |
| 366 |
23051187 | Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis. | 2012 Nov |
3 |
| 367 |
23055361 | [Novel therapeutic options in the treatment of BCR/ABL-negative myeloproliferative neoplasms]. | 2012 Oct |
1 |
| 368 |
23061804 | Ruxolitinib: in the treatment of myelofibrosis. | 2012 Nov 12 |
1 |
| 369 |
23119228 | Emerging therapeutic options for myelofibrosis: a Canadian perspective. | 2012 |
1 |
| 370 |
23186315 | Emerging drugs for myelofibrosis. | 2012 Dec |
1 |
| 371 |
23238141 | Janus activated kinase inhibition in myelofibrosis. | 2012 Jul-Sep |
2 |
| 372 |
21079613 | JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations. | 2011 Feb |
4 |
| 373 |
21635221 | A potential role of ruxolitinib in leukemia. | 2011 Aug |
2 |
| 374 |
21677670 | Preclinical evaluation of local JAK1 and JAK2 inhibition in cutaneous inflammation. | 2011 Sep |
1 |
| 375 |
21919691 | Ruxolitinib: a new JAK1/2 inhibitor that offers promising options for treatment of myelofibrosis. | 2011 Sep |
3 |
| 376 |
22034658 | Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis. | 2011 Dec |
2 |
| 377 |
22146225 | Ruxolitinib for the treatment of myelofibrosis. | 2011 Nov |
3 |
| 378 |
22362131 | Clinical and laboratory features of myelofibrosis and limitations of current therapies. | 2011 Sep |
1 |
| 379 |
20130243 | Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. | 2010 Apr 15 |
1 |
| 380 |
20506062 | Ruxolitinib, a selective JAK1 and JAK2 inhibitor for the treatment of myeloproliferative neoplasms and psoriasis. | 2010 Jun |
3 |
| 381 |
20843246 | Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. | 2010 Sep 16 |
2 |